Novartis AG Says Cancer Drug Kymriah Study Shows Efficacy, Safety
December 09 2019 - 4:30PM
Dow Jones News
By Maria Armental
Novartis AG said its cancer drug Kymriah showed consistent
efficacy and safety outcomes when used in real-world settings on a
broader group of U.S. patients.
The analyses are from a readout of a 15-year post-marketing
study looking at Kymriah in adults with relapsed or refractory
diffuse large B cell lymphoma, the most common type of lymphoma,
and in children and young adults with relapsed or refractory B-cell
acute lymphoblastic leukemia.
Kymriah (tisagenlecleucel), which company officials expect to
reach blockbuster potential over the next five years, is part of a
type of therapies known as Car-T that use genetically engineered
T-cells to attack the blood cancer.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
December 09, 2019 16:15 ET (21:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024